Recombinant Production of Human Microsomal Cytochrome P450 2D6 in the Methylotrophic Yeast Pichia pastoris
- 26 October 2005
- journal article
- research article
- Published by Wiley in ChemBioChem
- Vol. 6 (11) , 2014-2022
- https://doi.org/10.1002/cbic.200500200
Abstract
Microsomal cytochrome P450 monooxygenases of groups 1–3 are mainly expressed in the liver and play a crucial role in phase 1 reactions of xenobiotic metabolism. The cDNAs encoding human CYP2D6 and human NADPH-P450 oxidoreductase (CPR) were transformed into the methylotrophic yeast Pichia pastoris and expressed with control of the methanol-inducible AOX1 promoter. The determined molecular weights of the recombinant CYP2D6 and CPR closely matched the calculated values of 55.8 and 76.6 kDa. CPR activity was detected by conversion of cytochrome c by using isolated microsomes. Nearly all of the recombinant CYP was composed of the active holoenzyme, as confirmed by reduced CO difference spectra, which showed a single peak at 450 nm. Only by coexpression of human CPR and CYP was CYP2D6 activity obtained. Microsomes containing human CPR and CYP2D6 converted different substrates, such as 3-cyano-7-ethoxycoumarin, parathion and dextrometorphan. The kinetic parameters of dextrometorphan conversion closely matched those of CYP2D6 from other recombinant expression systems and human microsomes. The endogenous NADPH-P450 oxidoreductase of Pichia pastoris seems to be incompatible with human CYP2D6, as expression of CYP2D6 without human CPR did not result in any CYP activity. These recombinant strains provide a novel, easy-to-handle and cheap source for the biochemical characterisation of single microsomal cytochromes, as well as their allelic variants.Keywords
This publication has 43 references indexed in Scilit:
- Yeast and drug discoveryFunctional & Integrative Genomics, 2002
- Simulation of human xenobiotic metabolism in microorganisms: Yeast a good compromise between E. coli and human cellsJournal of Hepatology, 1997
- Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugsAdvanced Drug Delivery Reviews, 1997
- “It's the genes, stupid” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphismLife Sciences, 1995
- High yield expression of functionally active human liver CYP2D6 in yeast cellsPharmacogenetics, 1995
- Enhanced in vivo monooxygenase activities of mammalian P450s in engineered yeast cells producing high levels of NADPH-P450 reductase and human cytochrome b5Gene, 1993
- Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6Pharmacogenetics, 1993
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidationXenobiotica, 1986
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970